Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Bryet Us, Inc.

Clinical trials sponsored by Bryet Us, Inc., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers? Results expected Aug 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1

Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?

Disease control Not yet recruiting

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control

Last updated Jul 25, 2026 00:00 UTC